Back to search

Democritus University of Thrace (DUTH)

Στάσεις και απόψεις των ιατρών για τη φαρμακευτική καινοτομία και επίδραση στη συνταγογραφική τους συμπεριφορά: προσδιοριστικοί παράγοντες και επιπτώσεις για τη φαρμακευτική πολιτική

Abstract

dc:description

Introduction and Objectives: New pharmaceutical technology is an important determinant of pharmaceutical expenditure growth; at the same time, new drugs have significantly contributed to improved patient outcomes and have substituted other types of health care. The diffusion of new pharmaceutical technology affects pharmaceutical expenditure growth as well as patients’ outcomes and access to new medications. Hence, the study of new drug diffusion is of importance for pharmaceutical policy. The present study aims to explore factors influencing new drug adoption by prescribing physicians in the Greek health care context. Material and Methods: A systematised literature review was performed in order to identify factors affecting new drug adoption and inform the design of the primary research. The latter employed a mixed methods approach and used a theoretical framework which was developed based primarily on the Diffusion of Innovation Theory and complemented by two frameworks on the implementation of health services innovations and evidence-based interventions. The qualitative study focused on the adoption of new antidiabetic medicines that are used in the management of Type 2 Diabetes Mellitus (T2DM), whereas the quantitative study focused on adoption of a new class of antidiabetic medications, the Sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors). In both the qualitative and quantitative study, the samples comprised of physicians involved in the management of T2DM in adults. In the qualitative study, semi-structured interviews were performed. Eligible participants were identified using generic purposive sampling. Interviews were audio-recorded, transcribed verbatim and analysed using framework analysis. The results of the analysis and the findings of the literature review informed the development of the closed questionnaire that was used in the quantitative study. The questionnaire was developed in electronic format. Convenience sampling was employed. In specific, recruitment of participants was performed via four medical Scientific Societies which forwarded to their members’ e-mail addresses an invitation letter and the link to the electronic questionnaire. Identification of participants in the survey was not possible as questionnaire completion was anonymous. Results: 10 physicians were interviewed in the qualitative study. The mean interview duration was 44 minutes. The following main themes were derived: 1) Perceptions on pharmaceutical innovation, 2) Use of information sources and the new drug adoption process, 3) Factors influencing prescribing of new medicines for T2DM, and 4) Attitudes towards recently introduced pharmaceutical policy measures aimed at influencing prescribing behaviour. The qualitative study revealed that new drug adoption is not an instantaneous decision, rather it is a process. During this process, prescribers combined information on newer antidiabetic drugs from a variety of information sources; the perceived credibility of each source was important in the process of information-seeking. Framework analysis also brought forward a wide range of factors influencing new drug adoption; the attributes of the new drug, patient-related factors, external influences and prescriber needs and characteristics affected the adoption decision. The new drug’s perceived relative advantage was a critical factor for its adoption by participants in the qualitative study. The relative importance of this attribute was also dependent on its compatibility with the prescriber’s needs, values and practices. Other factors that affected adoption of newer antidiabetic drugs included the drug’s price compared to available pharmacotherapies (mostly in terms of its impact on the level of patient cost-sharing), patient clinical and socioeconomic characteristics as well as preferences, and prescribers’ personal characteristics. The final sample in the quantitative study consisted of 259 physicians. Mean age was 49.3 years (SD=9.1 years). 56.4% of participants were male. 81.9% of participants systematically prescribed SGLT2 inhibitors, whereas 13.9% replied that they prescribed SGLT2 inhibitors tentatively. 3.9% did not prescribe this class of drugs, although they were familiar with them. The results of the statistical analysis of responses to the questionnaire survey support the qualitative research findings on the importance of the perceived attributes of the new drugs and prescriber characteristics on new drug adoption. In both logistic and linear regression analyses perceived relative advantage of SGLT2 inhibitors had a significant separate effect on the stage of adoption and the (self-reported) percentage of T2DM patients being prescribed SGLT2 inhibitors. In addition, prescribers reporting lower perceived complexity of this class of drugs had higher odds of systematically prescribing SGLT2 inhibitors. Other factors that had a significant separate effect on adoption of SGLT2 inhibitors were related to prescriber characteristics, namely: the number of years of working experience (as approximated by number of years since completing their specialisation), participation in conferences on diabetes care as an author of a scientific presentation, the degree to which participants perceived that it was easy for them to stay up-to-date with developments regarding newer antidiabetic drugs and, finally, having participated in a phase III or IV study of SGLT2 inhibitors. Conclusions: Understanding the process and factors influencing new drug adoption is important for the development of pharmaceutical policy measures that will promote rational diffusion and use of new drugs. The results of the present study contribute to the development of such policies in Greece, by identifying determinants of new drug adoption in the management of T2DM and bringing forward issues that need to be addressed such as the importance of ensuring access by prescribers to high-quality and credible information on newly marketed drugs, considering aspects of value that are important to patients and physicians when appraising new drugs and the need for deliberate planning and implementation of a comprehensive policy for managing pharmaceutical innovation, part of which are measures aiming at changing prescribing behaviour. The present study is the first study to explore new drug adoption in Greece, employing a mixed methods approach. Future research could investigate prescribing of other new drug classes and/or use of new health technologies, thus contributing to better understanding of health technology adoption in the Greek context.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karampli, Eleftheria
  • Καραμπλή, Ελευθερία

Subjects

dc:subject × 24

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/47494

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karampli, Eleftheria; Καραμπλή, Ελευθερία. Στάσεις και απόψεις των ιατρών για τη φαρμακευτική καινοτομία και επίδραση στη συνταγογραφική τους συμπεριφορά: προσδιοριστικοί παράγοντες και επιπτώσεις για τη φαρμακευτική πολιτική. Democritus University of Thrace (DUTH), 2020. http://hdl.handle.net/10442/hedi/47494